Clinical Practice Guideline

Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources

February 17, 2020

Full Guideline: Pharmacological Management of Osteoporosis in Postmenopausal Women
JCEM: May 2019 (online March 2019)

Richard Eastell, Clifford J. Rosen (chair), Dennis M. Black, Angela M. Cheung, M. Hassan Murad, and Dolores Shoback

Guideline Update: Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update
JCEM: March 2020 (online February 2020)

Dolores Shoback, Clifford J. Rosen (chair), Dennis M. Black, Angela M. Cheung, M. Hassan Murad, and Richard Eastell

The guideline on pharmacological management of osteoporosis in postmenopausal women:

  • Provides recommendations for the treatment and management of osteoporosis in postmenopausal women
  • Emphasizes assessment after being on treatments to see if further treatment is necessary


Resources

Guideline Introduction | ENDO 2019


Essential Points

  • Treat high risk individuals - particularly those with previous fracture.
  • Consider bisphosphonates as the first line therapeutic choice for postmenopausal women at high risk of fracture.
  • Reassess fracture risk after patient has been on bisphosphonates for 3-5 years.
  • Following reassessment, prescribe a “bisphosphonate holiday” for women who are on bisphosphonates and are low-to-moderate risk of fracture.
  • Consider anabolic therapy (teriparatide or abaloparatide) for women at very high risk of fractures, including those with multiple fractures.
  • All women undergoing treatment with osteoporosis therapies other than anabolic therapy should consume calcium and vitamin D in their diet or via supplements.
  • Monitor the BMD of high-risk individuals with a low BMD every 1 to 3 years.

List of Recommendations

+ 1.0 Who to Treat

+ 2.0 Bisphosphonates

+ 3.0 Denosumab

+ 4.0 Teriparatide and Abaloparatide—Parathyroid Hormone and Parathyroid Hormone-Related Protein (PTHrP) Analogs

+ Update A (2020). Romosozumab

+ 5.0 Selective Estrogen Receptor Modulators

+ 6.0 Menopausal Hormone Therapy and Tibolone

+ 7.0 Calcitonin

+ 8.0 Calcium and Vitamin D

+ 11.0 Monitoring

CME

Certified Medical Minute

Watch this expert CME/CE-certified presentation highlighting expert recommendations on the variety of continuous glucose monitoring devices for optimizing management of individual patients with type 1 and type 2 diabetes

Comparison of Available and Emerging CGM Technology

Watch this expert CME/CE-certified presentation highlighting expert recommendations on the variety of continuous glucose monitoring devices for optimizing management of individual patients with type 1 and type 2 diabetes

Meetings

Submit Your ENDO 2021 Abstract

We have extended our abstract submission deadline to Monday, November 2. With over 150 topical areas for abstract submissions, don’t miss this chance to share your science and expand the reach of your work. Please use these extra few days to finalize your abstract and complete your submission.

We have extended our abstract submission deadline to Monday, November 2. With over 150 topical areas for abstract submissions, don’t miss this chance to share your science and expand the reach of your work. Please use these extra few days to finalize your abstract and complete your submission.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!